专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2023057653A1 TRPS1 INHIBITOR FOR USE IN THE TREATMENT OF RHABDOMYOSARCOMA 审中-公开
公开(公告)号：WO2023057653A1
公开(公告)日：2023-04-13
申请号：PCT/EP2022/078144
申请日：2022-10-10
申请人： LEIBNIZ-INSTITUT FÜR ALTERNSFORSCHUNG - FRITZ-LIPMANN-INSTITUT E.V. (FLI)
发明人： VON MALTZAHN, Julia , HÜTTNER, Sören , VON EYSS, Björn
IPC分类号： C12N15/113 , A61K31/7088 , C12N2310/141
摘要： The invention relates to a Tricho-Rhino-Phalangeal Syndrome Type I Protein (TRPS1) inhibitor for use in the treatment of a rhabdomyosarcoma, preferably in a human subject. Preferably, the rhabdomyosarcoma is an embryonal rhabdomyosarcoma (EMRS). In embodiments, the TRPS1 inhibitor reduces TRPS1 levels in rhabdomyosarcoma cells. In embodiments, the TRPS1 inhibitor is a TRPS1-suppressive oligonucleotide, such as an antisense oligonucleotide, a microRNA (miR), an shRNA, an siRNA, or a guide-RNA in conjunction with an RNA-guided endonuclease, or a nucleic acid molecule suitable for expression of a TRPS1-suppressive oligonucleotide, such as an expression plasmid encoding a TRPS1-suppressive oligonucleotide.

2. 发明申请

WO2022248097A1 PLASMAQUELLE ZUR HANDDESINFEKTION 审中-公开
公开(公告)号：WO2022248097A1
公开(公告)日：2022-12-01
申请号：PCT/EP2022/057487
申请日：2022-03-22
申请人： DBD PLASMA GMBH
发明人： DAMM, Roland , GREDNER, Alexander , HAESE, Christian , HAESE, Jürgen
IPC分类号： A61L2/14 , A61L2/00 , A01N25/34 , H05H1/24
摘要： Die Erfindung betrifft bevorzugt eine Vorrichtung, die Körperbereiche, insbesondere Hände, berührungslos trocknet und desinfiziert. Die desinfizierende Wirkung wird von einem Plasmagenerator gebildet, welcher einen zur Handtrocknung erwärmten Luftstrom den desinfizierenden Effekt verleiht. Der Plasmagenerator erzeugt bevorzugt reaktive Plasmaspezies, die durch den Luftstrom an die menschliche Haut gebracht werden. Der Kontakt mit der Plasmaquelle und Hochspannungsbauteilen wird vermieden. Darüber hinaus betrifft die Erfindung eine Verwendung der erfindungsgemäßen Vorrichtung und ein Verfahren zum Desinfizieren menschlicher Haut.

3. 发明申请

WO2022243459A1 COMPUTER ASSISTED METHOD FOR THE EVALUATION OF CARDIAC METABOLISM 审中-公开
公开(公告)号：WO2022243459A1
公开(公告)日：2022-11-24
申请号：PCT/EP2022/063620
申请日：2022-05-19
申请人： CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN
发明人： BERNDT, Nikolaus , KÜHNE, Titus
IPC分类号： G16H50/30 , G16H50/50 , G01N33/68 , G01N33/574 , G16B5/00
摘要： The invention relates to a computation based method for determining an individual cardiac metabolic profile in a subject and related materials, devices and mathematical model usage. The present invention therefore relates to a computation-based method for determining an individual metabolic cardiac profile of a subject comprising provision of a heart tissue sample from said subject, quantifying proteins in said sample from said subject, and applying information about quantities of said proteins to a mathematical model. In some embodiments, individual cardiac parameters and/or the metabolites of the subject are additionally introduced into the mathematical model, wherein individual cardiac parameters are determined for a plurality of cardiac workloads, including rest, stress or cardiac pacing. The invention also relates to the individual cardiac metabolic profile comprising a substrate uptake rate, a myocardial ATP consumption, a myocardial ATP production reserve, a myocardial ATP production at said cardiac workload, and a myocardial ATP production at maximal workload, wherein the myocardial ATP production reserve is calculated as the difference between the myocardial ATP- production at said cardiac workload and the myocardial ATP production at maximal workload. The invention further relates to the medical use and corresponding therapeutic methods based on the individual metabolic cardiac profile of the invention in the treatment, prevention, ascertainment, prognosis, of a medical condition associated with a cardiovascular disorder, in addition to detect a perturbation of a normal biological state of the heart from the subject. The invention further relates to the medical use and corresponding therapeutic methods based on the individual metabolic cardiac profile of the invention for the heart at physiological state and/or at pathological state. In further aspects, the invention relates to a computer program adapted to execute a mathematical modelling algorithm that will be performed by a computing device/module to produce outputs given data provided as inputs according to preceding claims, wherein said computer program, preferably MATLAB, is written in a programming language selected from a group comprising Fortran, C#, C/C++, High Level Shading Language, or Python.

4. 发明申请

WO2022243075A1 METHODE ZUR HERSTELLUNG MESOPORÖSER ÜBERGANGSMETALLKARBIDSCHICHTEN MIT DEFINIERTER NANOSTRUKTURIERUNG SOWIE DEREN ANWENDUNG IN DER ELEKTROKATALYSE 审中-公开
公开(公告)号：WO2022243075A1
公开(公告)日：2022-11-24
申请号：PCT/EP2022/062407
申请日：2022-05-09
申请人： TECHNISCHE UNIVERSITÄT BERLIN
发明人： FRISCH, Marvin , KRÄHNERT, Ralph
IPC分类号： B01J23/30 , B01J27/22 , B01J35/00 , B01J35/10 , B01J37/00 , B01J37/02 , B01J37/08 , B01J37/16 , B01J37/18
摘要： Die Erfindung betrifft ein Verfahren zur Herstellung mesoporöser Metallkarbidschichten mit definierter Nanostrukturierung, wobei in einem ersten Schritt des Verfahrens mesoporöse Metalloxidschichten bereitgestellt werden und in einem zweiten Schritt ein In-Kontakt-bringen der Metalloxidschicht in einer reduzierenden Atmosphäre – mit einer Kohlenstoffquelle in der Atmosphäre - erfolgt, wobei die Temperatur mindestens 650 °C beträgt und die Aufheizrate zwischen 0,5 – 2 Kelvin pro Minute liegt.

5. 发明申请

WO2022223778A1 CITRACONIC ACID AND DERIVATIVES THEREOF FOR USE AS A MEDICAMENT 审中-公开
公开(公告)号：WO2022223778A1
公开(公告)日：2022-10-27
申请号：PCT/EP2022/060682
申请日：2022-04-22
申请人： HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH
发明人： PRESSLER, Frank , CHEN, Fangfang , WINTERHOFF, Moritz , BÜSSOW, Konrad , BLANKENFELD, Wulf , HIRSCH, Anna , ELGAHER, Walid A. M.
IPC分类号： A61K31/194 , A61K31/22 , A61P11/00 , A61P31/12 , A61P31/14 , A61P35/00 , C07C69/00
摘要： The invention relates to citraconic acid (CA) or derivative thereof for use as medicament. The invention further relates to citraconic acid or derivative thereof for use in the treatment of a medical condition associated with inflammation. In another aspect, the invention relates to a citraconic acid derivative according to formulae l-XIII. In another aspect, the invention relates to a pharmaceutical composition comprising citraconic acid or derivative thereof with one or more pharmaceutical excipients for use in the treatment of a medical condition, such as those associated with inflammation and/or a non-inflammation associated medical condition.

6. 发明申请

WO2022223516A1 VERFAHREN ZUR HERSTELLUNG VON KOMPLEX-ARRAYS 审中-公开
公开(公告)号：WO2022223516A1
公开(公告)日：2022-10-27
申请号：PCT/EP2022/060239
申请日：2022-04-19
申请人： BIOCOPY GMBH
发明人： KRÄMER, Stefan Daniel , ROTH, Günter , WÖHRLE, Johannes
IPC分类号： B01J19/00
摘要： Die Erfindung beschreibt eine Hochdurchsatz-Methode zur simultanen und gezielten Vermischung eines Moleküls mit einer Vielzahl anderer Moleküle. Die dadurch entstandenen Molekül-Molekül Komplexe können anschließend an einer Oberfläche abgefangen werden, wodurch ein Mikroarray erzeugt wird. Dieses Mikroarray kann dann verwendet werden, um die Molekül-Molekül Komplexe zu charakterisieren und zu vermessen (z.B. auf Reaktionen zu anderen Molekülen).

7. 发明申请

WO2022171732A1 COMPOSITION AND METHOD FOR REDUCING OXALATE LEVELS IN PATIENTS RECEIVING MAINTENANCE DIALYSIS 审中-公开
公开(公告)号：WO2022171732A1
公开(公告)日：2022-08-18
申请号：PCT/EP2022/053225
申请日：2022-02-10
申请人： CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN
发明人： KNAUF, Felix , PFAU, Anja
IPC分类号： A61K31/713 , A61P13/12
摘要： The invention relates to a composition comprising Lumasiran and/or Nedosiran for use in the treatment or prevention of an oxalate-related disorder in a patient receiving dialysis treatment who does not suffer from Primary Hyperoxaluria 1-3 (PH), preferably a cardiovascular disease. In further aspects of the invention, the composition comprising Lumasiran and Nedosiran diminishes or blocks hepatic oxalate production in non-PH dialysis receiving patients to prevent or treat cardiovascular events, sudden cardiac death, congestive heart failure, and excess mortality in said patients. The invention further relates to administration, a method for preparing the composition comprising Lumasiran and/or Nedosiran and a kit comprising Lumasiran and/or Nedosiran and instructions for its use.

8. 发明申请

WO2022136551A1 REPROGRAMMING IMMUNE CELLS BY TARGETED INTEGRATION OF ZETA-DEFICIENT CHIMERIC ANTIGEN RECEPTOR TRANSGENES 审中-公开
公开(公告)号：WO2022136551A1
公开(公告)日：2022-06-30
申请号：PCT/EP2021/087306
申请日：2021-12-22
申请人： CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN
发明人： KATH, Jonas Christian , REINKE, Petra , SCHMÜCK-HENNERESSE, Michael , VOLK, Hans-Dieter , WAGNER, Dimitrios Laurin
IPC分类号： C07K14/725 , C12N9/22 , A61K35/17 , A61P35/00 , C12N5/0783
摘要： The invention relates to a nucleic acid construct for targeting and integrating a CD3 zeta-deficient chimeric antigen receptor (CAR) fragment into an endogenous CD3 zeta/CD247 gene of a host genome. The invention further relates to a genetically modified human cell expressing an exogenous nucleic acid sequence encoding a CD3 zeta deficient CAR fragment, integrated in- frame into the endogenous CD3 zeta/CD247 gene for gene fusion, to form a functional CAR comprising an exogenous CAR fragment fused with an endogenous CD3 zeta domain.

9. 发明申请

WO2022069523A1 RESCUE OF RECOMBINANT ADENOVIRUSES BY CRISPR/CAS-MEDIATED IN VIVO TERMINAL RESOLUTION 审中-公开
公开(公告)号：WO2022069523A1
公开(公告)日：2022-04-07
申请号：PCT/EP2021/076757
申请日：2021-09-29
申请人： ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG
发明人： RUZSICS, Zsolt , RIEDL, André , FISCHER, Julian , BURGERT, Hans-Gerhard
IPC分类号： C12N15/861 , C12N15/87 , C12N15/86 , C12N2310/20 , C12N2710/10343 , C12N2710/10345 , C12N2710/10351
摘要： The invention relates to circular DNA molecule for rescuing recombinant adenoviruses comprising a recombinant adenoviral genome with two inverted terminal repeats (ITRs) flanking the genome ends, wherein at least one of the ITRs is associated with a target sequence adjacent to a PAM sequence, wherein the target sequence is configured for generating an RNA-guided DNA endonuclease-mediated DNA double strand break at the external end of or in close proximity outside the external end of the respective ITR, preferably within less than about (15) nucleotides. The invention also relates to a kit and a method for rescuing recombinant adenoviruses comprising or using a circular DNA molecule as described herein.

10. 发明申请

WO2022043315A1 A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6 审中-公开
公开(公告)号：WO2022043315A1
公开(公告)日：2022-03-03
申请号：PCT/EP2021/073369
申请日：2021-08-24
申请人： CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN
发明人： PECHER, Gabriele , RAFTERY, Martin
IPC分类号： A61K39/00 , C07K14/725 , A61P35/00 , C07K14/54
摘要： The invention relates to a recombinant nucleic acid expression construct comprising a first nucleic acid sequence region encoding a chimeric antigen receptor (CAR), a second nucleic acid sequence region encoding a checkpoint inhibitory molecule, and a third nucleic acid sequence region encoding an immune stimulatory cytokine. The invention further relates to a recombinant nucleic acid expression construct encoding the CAR of the invention that specifically recognizes CD44v6, and comprises a PD1 checkpoint inhibitory molecule, and an immune stimulating cytokine. In further aspects, the invention relates to genetically modified cells, comprising a recombinant nucleic acid expression construct encoding said CAR, wherein the cells are preferably immune cells, more preferably NK cells or cytotoxic T lymphocytes or T helper cells. The invention further relates to corresponding medical uses of said cells in the treatment of a medical disorder associated with the presence of pathogenic cells expressing CD44v6, preferably cancer cells, more preferably cancer stem cells of solid or liquid malignancies.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式